Percutaneous management of vascular access in transfemoral transcatheter aortic valve implantation

Table 2 Incidence of major vascular access site complications and specific vascular access site types across transfemoral transcatheter aortic valve implantation studies

Ref.	Bioprostheses	Population	Major vascular complications	Stenosis/ occlusion	Perforation/rupture	Dissection	Pseudoaneurysm
Webb et al[40], Circulation 2009	ESV	113	9/113 (8%)	NA	NA	NA	NA
Ducrocq et al[8], Eurointervention 2010	ESV	54	9/54 (16.7%)	0/9	5/9 (55.5%)	4/9 (45.5%)	0/9
Tchetche et al[9], Eurointervention 2010	ESV + MCV	45 24 ESV 21 MCV	4/45 (8.9%) 2/24 (8.3%) ESV 2/21 (9.5%) MCV1	NA	NA	NA	NA
Piazza et al[41], Eurointervention 2008	MCV	646	12/646 (1.9%)	NA	NA	NA	NA
Himbert et al[42], JACC 2009	ESV	51	6/51 (12%)	0/6	2/6 (33%)	4/6 (66%)	0/6
Webb et al[1], Circulation 2007	ESV	50	4/50 (8%)	0/4	4/4 (100%)	0/4	0/4
SOURCE registry[43], Circulation 2009	ESV	463	57/463 (12.3%)	NA	NA	NA	NA
Lefèvre et al[44], Eur Heart J 2011	ESV	61	17/61 (28%)	0/61	3/61 (5%)	6/61 (10%)	1/161 (2%)
Canadian experience[45], JACC 2010	ESV	168	22/168 (13.1%)	NA	NA	NA	NA
Bleiziffer et al[46], J ThoracCardiovasc Surg 2009	MCV	153	24/153 (16%)	NA	NA	NA	NA
The Milan experience JACC Cardiovasc Interv 2010[47]	ESV + MCV	107 61 ESV 46 MCV	22 /107 (20.6%) 13/61 (21.3%) ESV 9/46 (19.5%) MCV1	1/22 (4.5%) ESV	7/22 (32%) 5/13 (38%) ESV 2/9 (22%) MCV1	6/22 (27%) 4/13 (31%) ESV 2/9 (22%) MCV1	4/22 (18%) MCV
The Rotterdam experience[7], Eurointervention 2010	MCV	99	13/99 (13%)	NA	NA	NA	NA
The France Registry[48], Eur Heart J 2011	ESV + MCV	160 94 ESV 66 MCV	11/160 (7%) 6/94 (6.4%) ESV 5/66 (7.6%) MCV1	0/11	2/11 (18%) ESV	7/11 (64%) 4/6 (67%) ESV 3/5 (60 %) MCV1	0/11
Petronio et al[49], Circ Cardiovasc Interv 2010	MCV	460	9/460 (2%)	NA	NA	NA	NA
Spanish experience[50], Rev Espan Cardiol 2010	MCV	108	6/108 (5.6%)	1/6 (16.6%)	1/6 (16.6%)	0/6	1/6 (6.60%)
United Kingdom Registry[51], JACC 2011	ESV + MCV	599 193 ESV 406 MCV	50/599 (8.4%)	NA	NA	NA	NA
Toggweiler et al[15], JACC 2012	ESV+ MCV	137 126 ESV 11 MCV	24/137 (18%)2	16/24 (66.6%)	2/24 (8.3%)	2/24 (8.3%)	2/24 (8.3%)
Partner trial[52], JACC 2012	ESV	419	64/419 (15.3%)	NA	20/64 (31.3%)	40/64 (62.8%)	2/64 (3.4%)
The France II Registry[53], NEJM 2013	ESV + MCV	3195 2107 ESV 1043 MCV	150/3195 (4.7%) 57/2107 (2.7%) 47/1043 (4.5%)	NA	NA	NA	NA
European Sentinel Registry of TAVI[54], Eurointervention 2013	ESV + MCV	4571 2604 ESV3 1943 MCV	40/4571 (3.1%) 20/2604 (3.3%) 20/1943 (2.8%)	NA	NA	NA	NA
Sawa et al[55], Circulation Journal 2014	MCV	44	5/44 (11.54%)	NA	NA	NA	NA
Spanish National Registry of TAVI[56], Rev Esp Cardiol 2013	ESV + MCV	1159 504 ESV 610 MCV	42/1159 (3.6%) 25/504 (5%) 17/610 (2.8%)	NA	NA	NA	NA
Total		12862	640/12862 (5%)	18/143 (12.6%)	44/207 (21.2%)	69/207 (33.3%)	10/207 (4.8%)

¹P value not significant between ESV and MCV subgroups;

²Major plus minor complications;

³Including transapical (29% of total ESV). ESV: Edwards SAPIEN valve; MCV: Medtronic Core Valve.